Shantha Biotech to hold clinical trials for new vaccine

By Staff
|
Google Oneindia News

Hyderabad, June 26 (UNI) Shantha Biotechnics expects to conduct clinical trials next year for its Rotavirus Vaccine to help children fight diarrhoea.

In a statement here today, Shantha Biotechnics said the trials will be held in collaboration with PATH, a global non-profit health organisation.

The company plans to carry out clinical trials following completion of pre-clinical toxicology studies for developing a multivalent vaccine against Rotavirus with a technology licensed from the US National Institute of Health (NIH).

''PATH is working with Shantha Biotechnics and other emerging manufacturers to develop safe, effective and affordable vaccines,'' the statement said.

Rotavirus is the most common cause of severe dehydrating diarrhoea responsible for more than 5.27 lakh deaths occurring annually in children under the age of five years, with majority of them in developing countries.

It is estimated the Rotavirus infections account for around 26 per cent of all diarrhoea-related hospitalisations in India with most of the cases occurring during the first two years of life and the incidence peaking at nine-11 months of age, it added.

UNI

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X